查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1827436

腦瘤藥物市場（按適應症、藥物類別、給藥途徑、最終用戶和分銷管道）—2025-2032 年全球預測

Brain Cancer Drugs Market by Indication, Drug Class, Route Of Administration, End User, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年腦癌藥物市場規模將成長至 39.3 億美元，複合年成長率為 7.64%。

主要市場統計數據
基準年2024年 21.8億美元
預計2025年 23.4億美元
預測年份：2032年 39.3億美元
複合年成長率（%） 7.64%

在快速的科學和商業性變革中製定腦癌治療的當前策略背景

腦腫瘤治療是腫瘤學中備受關注的領域，其驅動力來自亟待滿足的醫療需求和不斷加速的科學創新。臨床複雜性、血腦障壁障壁挑戰、診斷異質性以及監管環境的複雜變化，需要整合分子生物學、給藥技術和臨床試驗設計能力，才能達到轉化成功。最近的進展已將治療套件從細胞毒性藥物擴展到生物製藥、細胞療法以及旨在調節腫瘤微環境和免疫反應的標靶小分子。

從商業性角度來看，相關人員必須在高昂的開發成本、漫長的臨床路徑與特定病患群體獲得持續臨床效益的潛力之間取得平衡。付款人和衛生技術評估機構越來越重視真實世界證據和基於價值的契約，這更加重視核准後證據的生成和靈活的報銷安排。因此，策略規劃強調產品組合多元化、與監管機構和付款人的早期合作，以及對伴隨診斷和新型給藥平台的投資，以最大限度地提高臨床和商業性成功的可能性。

總的來說，引言強調了推進尖端科學的雙重挑戰，同時務實地解決商業化、獲取和交付挑戰，以確保創新技術轉化為積極的患者結果。

這是一個重大變革時期，將重新定義腦瘤藥物的整個治療方法和商業模式

近期趨勢表明，一些變革性變化正在改變開發者、臨床醫生和支付者對腦腫瘤治療的態度。精準腫瘤學利用分子譜識別可治療的變異，並為患者選擇策略提供資訊，它已經改變了臨床試驗設計，使生物標記主導的適應症成為可能，並從概念走向實踐。同時，免疫療法也日益成熟，癌症疫苗、CAR-T療法和查核點抑制劑正在中樞神經系統適應症的測試中。

同時，包括單株抗體和蛋白酪氨酸激酶抑制劑在內的標靶治療已透過創新的製劑策略和給藥載體適應了血腦障壁的限制。止吐藥和生長因子等支持性治療已成為患者綜合管理、提高耐受性和持續進行第一線治療的關鍵。數位健康、先進影像技術和液態切片的作用也得到了擴展，使得對疾病進展和治療反應的動態監測成為可能。總而言之，這些轉變需要新的營運模式、與診斷合作夥伴建立協作生態系統，並更加重視產生上市後證據以證明長期效益和價值。

評估 2025 年美國關稅對腦癌治療藥物供應鏈、定價和策略採購的累積影響

關稅的徵收給跨境供應鏈中的製藥商、委託製造和經銷商帶來了新的考慮。關稅變化可能會改變從國際供應商採購的活性藥物原料藥和輔料的相對成本結構，迫使企業重新評估供應商多元化、近岸外包和庫存策略。由於許多腦腫瘤治療依賴專門的原料、生物成分和與設備相關的輸送系統，因此投入成本的增加可能會透過製造時間表和合約定價結構產生連鎖反應。

此外，關稅將影響臨床試驗物流和臨床實驗藥物在臨床實驗地點之間的流動，可能增加管理費用，並需要提前製定緊急時應對計畫。付款人和採購團隊可能會透過收緊處方箋或強調成本效益數據來應對成本基準的變化，從而凸顯證明臨床價值差異的重要性。為此，產業相關人員正在採取各種策略，例如重新談判供應商合約、將生產轉移到關稅優惠的司法管轄區以及加速關鍵投入的在地化。最終，供應鏈的彈性和策略性採購決策在市場上佔據重要地位，成功的公司會優先考慮靈活透明的成本模型，以減輕關稅帶來的干擾。

按適應症、藥物類別、給藥途徑、最終用戶和分銷管道進行細分，可提供影響策略重點的見解

多形性膠質母細胞瘤因其侵襲性生物學特性而存在大量未滿足的醫療需求，而腦膜瘤、轉移性腦瘤和腦下垂體瘤則各自需要不同的治療方法和調控途徑。了解這些臨床差異可以改善標靶選擇和試驗設計。烷化劑、抗代謝物和植物鹼等藥物類別提供細胞毒機制，突顯了某些方案中化療的基本支柱。同時，包括癌症疫苗、CAR-T 療法和查核點抑制劑在內的化療提供了免疫介導的策略，可能在特定群體中產生持久的反應。包括止吐藥和生長因子在內的支持性治療在維持治療強度和患者生活品質方面發揮重要作用。標靶治療，包括單株抗體和蛋白酪氨酸激酶抑制劑，能夠精確標靶化致癌驅動因子和訊號通路。

按給藥途徑（鞘內、靜脈、口服）進行細分，可以考慮配方開發、患者依從性和設施要求，並有助於確定門診病人和住院給藥模式。按最終用戶（如診所、家庭醫療保健和醫院）進行細分，可以為營運規劃提供資訊，包括輸液能力、家庭給藥通訊協定和多學科團隊的培訓需求。按分銷管道進行細分，可以區分醫院藥房、線上藥房和零售藥房，每種藥房都有其獨特的合規性、低溫運輸和報銷接觸點，從而影響打入市場策略。整合這些細分市場使相關人員能夠優先考慮資源分配、完善臨床開發計劃，並使商業化方法與交付和存取的營運現實保持一致。

美洲、歐洲、中東和非洲以及亞太地區的區域動態和競爭格局塑造了市場進入和夥伴關係策略

由於法律規範、研究架構、臨床研究能力和醫療保健基礎設施的差異，區域動態存在顯著差異。在美洲，成熟的卓越中心和強大的臨床試驗網路支持新療法的早期應用，並促進快速患者累積，而付款方越來越需要來自真實世界臨床試驗結果的證據。在歐洲、中東和非洲，監管協調和國家衛生技術評估流程需要細緻的市場進入規劃和長期衛生經濟模型，以確保藥物納入處方集。在亞太地區，對癌症研究的快速投資、醫院容量的擴大以及本地製造能力的提升，既帶來了規模化發展的機會，也帶來了與異質監管途徑和定價環境相關的複雜性。

與學術中心和合約研究機構的合作支持在已開發市場進行轉化研究，而與區域經銷商和本地製造商的合作則有助於進入市場，因為本地生產或熟悉監管機構具有優勢。臨床應用受到診斷能力和護理標準實施差異的影響，這可能會影響生物標記主導療法的採用速度。因此，針對特定區域制定的策略，考慮到監管時機、報銷途徑和當地臨床實踐，對於有效部署腦腫瘤療法至關重要。

主要企業洞察

領先的製藥和生物技術公司正在加強多個領域的能力，以保持腦癌治療的勢頭。研發投資日益著重於增強中樞神經系統滲透性的平台、生物標記主導的病患選擇，以及標靶藥物與免疫調節劑合併用藥的聯合策略。各公司正透過專業的生產能力（包括病毒載體和細胞療法生產）實現差異化，並透過與診斷開發商的策略合作夥伴關係共同開發伴隨檢測，以實現精準註冊和標籤差異化。

共同研究模式明顯反映創新者、受託製造廠商、學術中心和生物技術合作夥伴之間建立風險共擔聯盟的趨勢。這些模式有助於獲取專業技能，加速早期開發，並降低後期專案的風險。產品組合策略強調在新的作用機制與現有資產之間取得​​平衡，以提高耐受性和療效持久性。此外，業務拓展活動也越來越強調對有前景的早期資產進行授權，以及有針對性地收購互補的給藥技術和診斷能力。總體而言，成功的組織會展示由策略外部夥伴關係關係支持的綜合臨床、監管和商業計劃。

為行業領導者提供切實可行的建議，以加強開發平臺、上市和以患者為中心的交付模式

行業領導者應優先考慮與監管機構和付款方進行早期和反覆的溝通，以就證據要求和可接受的終點達成一致，從而反映有意義的臨床益處。對伴隨診斷和標準化生物標記檢測法的投資將提高臨床試驗效率，並支持有針對性的標籤聲明。在營運方面，加強供應鏈冗餘並尋求區域製造夥伴關係可以降低關稅和物流風險，並加快臨床實驗藥物的臨床應用時間。

公司還應設計開發項目，建立強大的真實世界證據路徑，包括註冊研究和核准後研究，以支持持久的報銷協議。除了療效之外，強調耐受性和生活品質將向臨床醫生和付款人展示其價值。與家庭醫療保健提供者和醫院合作制定安全的給藥通訊協定，將擴大藥物的可近性並減輕患者的治療負擔。最後，採用靈活的商業模式，例如結果掛鉤合約和在地化定價策略，可以促進不同醫療保健系統的藥物可及性，同時確保商業性永續性。

透明的調查方法，解釋報告研究結果所依據的資料來源、分析方法和檢驗過程

調查方法整合了原始研究和二手資料，以實現全面覆蓋和洞察檢驗。原始研究包括對臨床研究人員、腫瘤藥劑師、付款人、醫院採購負責人和行業高管的結構化訪談，並輔以與諮詢委員會的磋商，以確定實踐模式和應用障礙。二手資料包括同行評審文獻、監管文件、臨床試驗註冊中心、會議記錄和公司披露資訊，以揭示技術趨勢、作用機制研發和監管先例。

分析方法包括定性主題分析（用於整合相關利益者的觀點）和定量橫斷面分析（用於考察不同細分市場和地區的應用模式）。為了減少偏誤並確認研究結果，我們採用了資料來源三角檢定和迭代同儕檢驗。本調查方法承認臨床情況不斷發展以及新科學進展與同行評審證據之間可能存在的滯後性，因此強調結論旨在為戰略決策提供資訊，而非提供規範的臨床指導。

整合臨床前景、商業性現實和對腦癌治療利害關係人的策略重要性的結論總結

總而言之，腦癌治療領域前景光明，但同時也面臨複雜的開發和商業化挑戰。精準醫療、免疫療法和給藥科學的發展拓展了治療策略的選擇，但成功的臨床轉化需要臨床開發、診斷、生產和支付方參與等方面的協調努力。供應鏈壓力和關稅趨勢正在推動策略採購和本地生產的考慮，而法規和報銷制度的地區差異則要求制定量身定做的上市方案。

我們將設計基於生物標記的臨床試驗，投資伴隨診斷和真實世界證據，增強生產和分銷的韌性，並尋求能夠實現互補的合作夥伴關係。透過將臨床創新與卓越營運和以付款人為中心的證據產生相結合，相關人員可以改善患者獲得有效治療的可及性，並在整個治療生態系統中創造永續的價值。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 將次世代定序生物標記整合到個人化膠質瘤治療選擇中
  • 對流增強輸送系統在局部腦腫瘤治療的應用日益增多
  • 復發性神經膠母細胞瘤血腦障壁滲透性小分子抑制劑的開發
  • 溶瘤病毒合併免疫查核點抑制劑治療腦腫瘤的臨床進展
  • 針對多種膠質瘤抗原的雙特異性抗體構建體的投資激增，有望改善治療效果
  • 引入人工智慧演算法最佳化腦腫瘤放射治療計畫和監測

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

第8章腦腫瘤藥物市場（按適應症）

  • 多形性膠質母細胞瘤
  • 腦膜瘤
  • 轉移性腦瘤
  • 腦下垂體瘤

第9章腦瘤藥物市場（依藥物類別）

  • 化療
    • 烷化劑
    • 抗代謝物
    • 植物生物鹼
  • 免疫療法
    • 癌症疫苗
    • CAR-T療法
    • 查核點抑制劑
  • 支持性護理
    • 止吐藥
    • 生長因子
  • 標靶治療
    • 單株抗體
    • 蛋白酪氨酸激酶抑制劑

第 10 章腦腫瘤藥物市場（依給藥途徑）

  • 椎管內
  • 靜脈
  • 口服

第 11 章腦腫瘤藥物市場（依最終使用者）

  • 診所
  • 家庭醫療保健
  • 醫院

第12章腦腫瘤藥物市場（依通路）

  • 醫院藥房
  • 網路藥局
  • 零售藥局

第13章腦瘤藥物市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章腦腫瘤藥物市場（依類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章腦瘤藥物市場（按國家）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • F. Hoffmann-La Roche Ltd
    • Merck & Co., Inc.
    • Bristol-Myers Squibb Company
    • Novartis AG
    • Pfizer Inc.
    • Johnson & Johnson
    • Bayer Aktiengesellschaft
    • AbbVie Inc.
    • Teva Pharmaceutical Industries Ltd
    • Amgen Inc.
Product Code: MRR-434CCDA05263

The Brain Cancer Drugs Market is projected to grow by USD 3.93 billion at a CAGR of 7.64% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 2.18 billion
Estimated Year [2025] USD 2.34 billion
Forecast Year [2032] USD 3.93 billion
CAGR (%) 7.64%

Framing the Current Strategic Context for Brain Cancer Therapeutics Amid Rapid Scientific and Commercial Change

The introduction positions brain cancer drugs as a high-priority area within oncology, driven by an urgent unmet medical need and accelerating scientific innovation. Clinical complexity, blood-brain barrier challenges, diagnostic heterogeneity, and regulatory expectations together create a landscape where translational success requires integrated capabilities across molecular biology, delivery technologies, and clinical trial design. Recent advances have expanded the therapeutic toolkit beyond cytotoxic agents to include biologics, cell therapies, and targeted small molecules that aim to modulate tumor microenvironments and immune responses.

From a commercial perspective, stakeholders must balance high development costs and protracted clinical pathways with the potential for durable clinical benefit in select patient populations. Payers and health technology assessment bodies are increasingly focused on real-world evidence and value-based contracting, which places a premium on post-approval evidence generation and adaptive reimbursement arrangements. Consequently, strategic planning now emphasizes diversified portfolios, earlier engagement with regulators and payers, and investment in companion diagnostics and novel delivery platforms to maximize the probability of clinical and commercial success.

Taken together, the introduction highlights the dual imperative: advancing cutting-edge science while pragmatically addressing commercialization, access, and delivery challenges to ensure that innovations translate into meaningful patient outcomes.

Major Transformative Shifts Redefining Treatment Approaches and Commercial Models Across Brain Cancer Therapeutics

Over recent years, several transformative shifts have altered how developers, clinicians, and payers approach brain cancer drugs. Precision oncology has moved from concept to practice as molecular profiling identifies actionable alterations and informs patient selection strategies, thereby changing clinical trial designs and enabling biomarker-driven indications. Concurrently, immunotherapeutic modalities have matured, with cancer vaccines, CAR-T approaches, and checkpoint inhibitors being tested in central nervous system indications; these modalities have prompted reconsideration of combination regimens and novel endpoints suited to immunologic mechanisms.

At the same time, targeted therapies, including monoclonal antibodies and tyrosine kinase inhibitors, have adapted to constraints imposed by the blood-brain barrier through innovative formulation strategies and delivery tools, which include both systemic modifications and localized administration methods. Supportive therapies, such as anti-emetics and growth factors, have become integral to comprehensive patient management, improving tolerability and enabling sustained delivery of primary agents. The role of digital health, advanced imaging, and liquid biopsies has also expanded, enabling more dynamic monitoring of disease trajectory and therapy response. Collectively, these shifts demand new operational models, collaborative ecosystems with diagnostic partners, and an increased emphasis on post-market evidence generation to demonstrate long-term benefit and value.

Assessing the Cumulative Impact of United States Tariffs in 2025 on Supply Chains, Pricing, and Strategic Sourcing in Brain Cancer Therapeutics

The imposition of tariffs has introduced new considerations for pharmaceutical manufacturers, contract manufacturers, and distributors that operate across transnational supply chains. Tariff changes can alter the relative cost structure of active pharmaceutical ingredients and excipients sourced from international suppliers, prompting firms to reassess supplier diversification, nearshoring, and stockpiling strategies. For brain cancer therapeutics-many of which rely on specialized raw materials, biologic components, or device-related delivery systems-any incremental input cost can cascade through manufacturing schedules and contractual pricing structures.

Moreover, tariffs have implications for clinical trial logistics and the movement of investigational medicinal products between study sites, potentially increasing administrative overhead and necessitating earlier contingency planning. Payers and procurement teams may respond to altered cost baselines by tightening formularies or emphasizing cost-effectiveness data, which underscores the importance of demonstrating differential clinical value. In response, industry players are pursuing strategies such as renegotiating supplier agreements, transferring select manufacturing steps to tariff-favored jurisdictions, and accelerating localization of critical inputs. Ultimately, the net effect is an increased premium on supply chain resilience and strategic sourcing decisions, with successful organizations prioritizing flexibility and transparent cost modeling to mitigate tariff-driven disruptions.

Insights Derived from Segmentation by Indication, Drug Class, Administration Route, End User, and Distribution Channel That Inform Strategic Priorities

Segmentation by indication clarifies heterogeneity in clinical need and development emphasis, with glioblastoma multiforme representing persistent unmet needs due to its aggressive biology, while meningioma, metastatic brain tumors, and pituitary tumors each require distinct therapeutic approaches and regulatory pathways. Understanding those clinical distinctions sharpens target selection and trial design. Segmentation by drug class highlights that chemotherapy remains a foundational backbone in some regimens, with alkylating agents, antimetabolites, and plant alkaloids delivering cytotoxic mechanisms. Meanwhile, immunotherapy modalities such as cancer vaccines, CAR-T therapy, and checkpoint inhibitors offer immune-mediated strategies that may provide durable responses in selected cohorts. Supportive therapy components like anti-emetics and growth factors play a critical role in maintaining dose intensity and patient quality of life. Targeted therapies, including monoclonal antibodies and tyrosine kinase inhibitors, enable precision targeting of oncogenic drivers and signaling pathways.

Route of administration segmentation-intrathecal, intravenous, and oral-drives considerations around formulation development, patient adherence, and facility requirements, and it informs decisions on outpatient versus inpatient delivery models. End user segmentation across clinics, home healthcare, and hospitals shapes operational planning for infusion capacity, home administration protocols, and training needs for multidisciplinary teams. Distribution channel segmentation differentiates hospital pharmacies, online pharmacies, and retail pharmacies, each presenting unique compliance, cold chain, and reimbursement touchpoints that influence market access strategies. By integrating these segment lenses, stakeholders can prioritize resource allocation, refine clinical development plans, and align commercialization approaches with the operational realities of delivery and access.

Regional Dynamics and Competitive Contexts Across the Americas, Europe, Middle East & Africa, and Asia-Pacific That Shape Market Entry and Partnership Strategies

Regional dynamics vary substantially, driven by differences in regulatory frameworks, reimbursement architectures, clinical research capacity, and healthcare infrastructure. In the Americas, established centers of excellence and robust clinical trial networks support early adoption of novel therapeutics and facilitate rapid patient accrual, while payers increasingly demand real-world outcome evidence. In Europe, Middle East & Africa, regulatory harmonization efforts and national health technology assessment processes require nuanced market access planning and long-term health economic modeling to secure formulary inclusion. In Asia-Pacific, rapid investments in oncology research, expanding hospital capacity, and growing local manufacturing capabilities present both scale opportunities and complexity related to heterogeneous regulatory pathways and pricing environments.

Across these regions, partnership models differ: collaborations with academic centers and contract research organizations support translational research in advanced markets, while alliances with regional distributors and local manufacturers enable market entry where localized production or regulatory familiarity is advantageous. Clinical adoption is influenced by variations in diagnostic capacity and standard-of-care practices, which can affect the pace of uptake for biomarker-driven therapies. Therefore, region-specific strategies that consider regulatory timing, reimbursement levers, and local clinical practice are essential for effective deployment of brain cancer therapeutics.

Key Company-Level Insights on Capabilities, Strategic Positioning, and Collaboration Models Driving Progress in Brain Cancer Therapeutics

Leading pharmaceutical and biotechnology companies are strengthening capabilities across several domains to sustain momentum in brain cancer therapeutics. R&D investments are increasingly concentrated on platforms that enhance central nervous system penetration, biomarker-driven patient selection, and combination strategies that pair targeted agents with immune modulators. Companies are differentiating through specialized manufacturing competencies, including viral vector and cell therapy production, as well as through strategic partnerships with diagnostic developers to co-develop companion assays that enable precise enrollment and label differentiation.

Collaboration models show a clear trend toward risk-sharing alliances between innovators, contract manufacturing organizations, academic centers, and biotechnology partners. These models facilitate access to niche expertise, accelerate early-phase development, and de-risk later-stage programs. Portfolio strategies favor a balance between novel mechanisms of action and assets that enhance tolerability or extend durability of response. Additionally, business development activity increasingly emphasizes in-licensing of promising early-stage assets and targeted acquisitions that complement delivery technologies or diagnostic capabilities. Overall, successful organizations demonstrate integrated clinical, regulatory, and commercial planning supported by strategic external partnerships.

Actionable Recommendations for Industry Leaders to Strengthen Development Pipelines, Market Access, and Patient-Centered Delivery Models

Industry leaders should prioritize early and iterative engagement with regulatory agencies and payers to align on evidence requirements and acceptable end points that reflect meaningful clinical benefit. Investing in companion diagnostics and standardized biomarker assays will improve trial efficiency and support targeted labeling claims. From an operational perspective, enhancing supply chain redundancy and pursuing regional manufacturing partnerships can mitigate tariff and logistic risks while shortening time-to-clinic for investigational products.

Companies should also design development programs that build robust real-world evidence pathways, including registries and post-approval studies, to support durable reimbursement agreements. Emphasizing tolerability and quality-of-life outcomes alongside efficacy will aid in demonstrating value to clinicians and payers. Collaboration with home healthcare providers and hospitals to develop safe administration protocols will expand access and reduce treatment burden for patients. Finally, adopting flexible commercial models-such as outcome-linked contracting and tailored regional pricing strategies-can facilitate access across diverse healthcare systems while protecting commercial sustainability.

Transparent Research Methodology Explaining Data Sources, Analytic Approaches, and Validation Processes That Underpin the Report's Findings

The research methodology integrates primary and secondary approaches to ensure comprehensive coverage and validation of insights. Primary research comprises structured interviews with clinical investigators, oncology pharmacists, payers, hospital procurement officers, and industry executives, supplemented by advisory board consultations to contextualize practice patterns and adoption barriers. Secondary research includes peer-reviewed literature, regulatory documents, clinical trial registries, conference proceedings, and company disclosures to map technological trends, mechanism of action developments, and regulatory precedents.

Analytical techniques include qualitative thematic analysis to synthesize stakeholder perspectives and quantitative cross-sectional analyses to examine adoption patterns across segments and regions. Triangulation of data sources and iterative validation with subject-matter experts are employed to reduce bias and confirm findings. The methodology acknowledges limitations related to the evolving clinical landscape and potential lag between emerging scientific developments and peer-reviewed evidence, and it emphasizes that conclusions are intended to inform strategic decision-making rather than provide prescriptive clinical guidance.

Concluding Synthesis That Integrates Clinical Promise, Commercial Realities, and Strategic Imperatives for Brain Cancer Drug Stakeholders

In conclusion, the brain cancer therapeutics landscape is characterized by significant scientific promise alongside complex developmental and commercialization challenges. Advances in precision medicine, immunotherapy, and delivery science have expanded the array of plausible therapeutic strategies, but successful translation into widespread clinical practice requires coordinated efforts across clinical development, diagnostics, manufacturing, and payer engagement. Supply chain pressures and tariff dynamics have added urgency to strategic sourcing and regional manufacturing considerations, while regional heterogeneity in regulatory and reimbursement systems demands tailored market access approaches.

To capitalize on emerging opportunities, organizations must combine scientific rigor with pragmatic commercial planning: design biomarker-enabled trials, invest in companion diagnostics and real-world evidence, strengthen manufacturing and distribution resilience, and pursue collaborative alliances that bring complementary capabilities. By aligning clinical innovation with operational excellence and payer-focused evidence generation, stakeholders can improve patient access to meaningful treatments and create sustainable value across the therapeutic ecosystem.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of next-generation sequencing biomarkers in personalized glioma therapy selection
  • 5.2. Rising adoption of convection-enhanced delivery systems for localized brain tumor treatments
  • 5.3. Development of blood-brain barrier-penetrating small molecule inhibitors for recurrent glioblastoma
  • 5.4. Clinical advancement of oncolytic virus therapies combined with immune checkpoint inhibitors in brain cancer
  • 5.5. Investment surge in bispecific antibody constructs targeting multiple glioma antigens for improved outcomes
  • 5.6. Deployment of artificial intelligence algorithms to optimize radiotherapy planning and monitoring in brain tumors

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Brain Cancer Drugs Market, by Indication

  • 8.1. Glioblastoma Multiforme
  • 8.2. Meningioma
  • 8.3. Metastatic Brain Tumors
  • 8.4. Pituitary Tumors

9. Brain Cancer Drugs Market, by Drug Class

  • 9.1. Chemotherapy
    • 9.1.1. Alkylating Agents
    • 9.1.2. Antimetabolites
    • 9.1.3. Plant Alkaloids
  • 9.2. Immunotherapy
    • 9.2.1. Cancer Vaccines
    • 9.2.2. CAR-T Therapy
    • 9.2.3. Checkpoint Inhibitors
  • 9.3. Supportive Therapy
    • 9.3.1. Anti-Emetics
    • 9.3.2. Growth Factors
  • 9.4. Targeted Therapy
    • 9.4.1. Monoclonal Antibodies
    • 9.4.2. Tyrosine Kinase Inhibitors

10. Brain Cancer Drugs Market, by Route Of Administration

  • 10.1. Intrathecal
  • 10.2. Intravenous
  • 10.3. Oral

11. Brain Cancer Drugs Market, by End User

  • 11.1. Clinics
  • 11.2. Home Healthcare
  • 11.3. Hospitals

12. Brain Cancer Drugs Market, by Distribution Channel

  • 12.1. Hospital Pharmacies
  • 12.2. Online Pharmacies
  • 12.3. Retail Pharmacies

13. Brain Cancer Drugs Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Brain Cancer Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Brain Cancer Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. F. Hoffmann-La Roche Ltd
    • 16.3.2. Merck & Co., Inc.
    • 16.3.3. Bristol-Myers Squibb Company
    • 16.3.4. Novartis AG
    • 16.3.5. Pfizer Inc.
    • 16.3.6. Johnson & Johnson
    • 16.3.7. Bayer Aktiengesellschaft
    • 16.3.8. AbbVie Inc.
    • 16.3.9. Teva Pharmaceutical Industries Ltd
    • 16.3.10. Amgen Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. BRAIN CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. BRAIN CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. BRAIN CANCER DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY GLIOBLASTOMA MULTIFORME, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY GLIOBLASTOMA MULTIFORME, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY GLIOBLASTOMA MULTIFORME, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY GLIOBLASTOMA MULTIFORME, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY GLIOBLASTOMA MULTIFORME, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY GLIOBLASTOMA MULTIFORME, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY MENINGIOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY MENINGIOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY MENINGIOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY MENINGIOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY MENINGIOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY MENINGIOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY METASTATIC BRAIN TUMORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY METASTATIC BRAIN TUMORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY METASTATIC BRAIN TUMORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY METASTATIC BRAIN TUMORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY METASTATIC BRAIN TUMORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY METASTATIC BRAIN TUMORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY PITUITARY TUMORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY PITUITARY TUMORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY PITUITARY TUMORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY PITUITARY TUMORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY PITUITARY TUMORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY PITUITARY TUMORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ANTIMETABOLITES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ANTIMETABOLITES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ANTIMETABOLITES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ANTIMETABOLITES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ANTIMETABOLITES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ANTIMETABOLITES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY PLANT ALKALOIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY PLANT ALKALOIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY PLANT ALKALOIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY PLANT ALKALOIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY PLANT ALKALOIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY PLANT ALKALOIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CANCER VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CANCER VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CANCER VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CANCER VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CANCER VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CAR-T THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CAR-T THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CAR-T THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CAR-T THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CAR-T THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CAR-T THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ANTI-EMETICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ANTI-EMETICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ANTI-EMETICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ANTI-EMETICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ANTI-EMETICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ANTI-EMETICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY GROWTH FACTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY GROWTH FACTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY GROWTH FACTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY GROWTH FACTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY GROWTH FACTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY GROWTH FACTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY INTRATHECAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY INTRATHECAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY INTRATHECAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY INTRATHECAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY INTRATHECAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY INTRATHECAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 188. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 189. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 190. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 191. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 192. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 193. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 194. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 195. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 196. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 197. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 198. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 199. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 200. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 201. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 202. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 203. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 204. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. NORTH AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 210. NORTH AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 212. NORTH AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 214. NORTH AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 215. NORTH AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 216. NORTH AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 218. NORTH AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 220. NORTH AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 221. NORTH AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 222. NORTH AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 224. NORTH AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 226. NORTH AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. LATIN AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. LATIN AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 230. LATIN AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 231. LATIN AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 232. LATIN AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 234. LATIN AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 235. LATIN AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 236. LATIN AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 237. LATIN AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 238. LATIN AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 240. LATIN AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 241. LATIN AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 242. LATIN AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 243. LATIN AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 244. LATIN AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 246. LATIN AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 287. MIDDLE EAST BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 288. MIDDLE EAST BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 289. MIDDLE EAST BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 290. MIDDLE EAST BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 291. MIDDLE EAST BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 292. MIDDLE EAST BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 293. MIDDLE EAST BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 294. MIDDLE EAST BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 295. MIDDLE EAST BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 296. MIDDLE EAST BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 297. MIDDLE EAST BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 298. MIDDLE EAST BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 299. MIDDLE EAST BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 300. MIDDLE EAST BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 301. MIDDLE EAST BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 302. MIDDLE EAST BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 303. MIDDLE EAST BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 304. MIDDLE EAST BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 305. MIDDLE EAST BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 306. MIDDLE EAST BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 307. AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 308. AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 309. AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 310. AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 311. AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 312. AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 313. AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 314. AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 315. AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 316. AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 317. AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 318. AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 319. AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 320. AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 321. AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 322. AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 323. AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 324. AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 325. AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION C